Diabetic Peripheral Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Diabetic Peripheral Neuropathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Peripheral Neuropathy - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline landscape.

Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legsand feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet pain ordiscomfort in the feet or legs-including prickly, sharp pain or burning feet, muscle weakness and loss of muscle tonein the feet and lower legs, loss of balance, dry feet and cracked skin. The predisposing factors include diabetes,smoking and kidney diseases. Treatment includes antidepressants, anti-seizure and opioid analgesics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Peripheral Neuropathy - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 9, 6, 10 and 3 respectively.

Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders)

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned
Companies Mentioned

Achelios Therapeutics Inc
Annji Pharmaceutical Co Ltd
Applied Therapeutics Inc
Celularity Inc
CSPC Pharmaceutical Group Ltd
Exodos Life Sciences Limited Partnership
G&P Bioscience Co Ltd
GNT Pharma Co Ltd
Grunenthal GmbH
Immune Pharmaceuticals Inc
Ion Channel Pharmacology LLC
Jiangsu Aosaikang Pharmaceutical Co Ltd
Korea United Pharm Inc
Medifron DBT Co Ltd
Mitsubishi Tanabe Pharma Corp
Palisade Bio, Inc
Praetego Inc
Pure Green Pharmaceuticals Inc
Reata Pharmaceuticals Inc
Shandong Huizhi Pharmaceutical Technology Co Ltd
Sonnet BioTherapeutics Holdings Inc
Sphaera Pharma Pte Ltd
Winsantor Inc
Zhejiang Pharmaceutical Co Ltd